[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraoperative-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraoperative-complications":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,102,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100531832","diagnostic-efficacy-of-cnn-in-predicting-intraoperative-complications-and-postoperative-outcomes-in-smile-100531832",false,"NCT06204926","Diagnostic Efficacy of CNN in Predicting Intraoperative Complications and Postoperative Outcomes in SMILE","Diagnostic Efficacy of Convolutional Neural Network Based Algorithm in Predicting Intraoperative Complications and Postoperative Outcomes in Small Incision Lenticule Extraction","Inclusion Criteria:\n\n* A condition in which the spherical equivalent refractive error of an eye is ≤-0.50 D when ocular accommodation is relaxed;\n* Age ≥18 years;\n* Spherical equivalent (SE) ≥-10.0D;\n* Corrected distance visual acuity (CDVA) ≥16\u002F20;\n* Stable myopia for at least 2 years;\n* No contact lenses wearing for at least 2 weeks.\n\nExclusion Criteria:\n\n* The presence or history of eye conditions other than myopia and astigmatism, such as keratoconus or external eye injury;\n* A history of eye surgery;\n* The presence or history of systemic diseases.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},1250,"ESTIMATED","OBSERVATIONAL","To evaluate the diagnostic efficiency of the neural network in predicting complications of Small Incision Lenticule Extraction in a multi-center cross-sectional study.",[26,27,28,29],"Deep Convolutional Neural Network","Small-incision Lenticule Extraction (SMILE) Surgery","Intraoperative Complications","Postoperative Outcomes",[31,28,26,29],"femtosecond laser small-incision lenticule extraction","RECRUITING","2026-04-21",{"date":35,"type":36},"2026-04-24","ACTUAL",{"date":38,"type":36},"2021-06-15",{"date":40,"type":22},"2027-12",{"name":42,"class":43},"Second Affiliated Hospital of Nanchang University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100632637","prospective-cohort-study-of-pheochromocytomaparaganglioma-100632637","NCT07516275","Prospective Cohort Study of Pheochromocytoma\u002FParaganglioma","Validation and Extension Study of the Predictive Model for Intraoperative Hemodynamic Instability in Pheochromocytoma\u002FParaganglioma Resection - a Single-center, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed with pheochromocytoma\u002Fparaganglioma by imaging and laboratory tests and scheduled for elective resection.\n* Planned intraoperative continuous invasive arterial pressure monitoring.\n* Willing and able to provide written informed consent.\n* Able to comply with preoperative CGM monitoring, AI agent assessment, and postoperative follow-up.\n\nExclusion Criteria:\n\n* Intraoperative hemodynamic data missing ≥20%.\n* Postoperative histopathology excludes PPGL diagnosis.\n* Cardiac paraganglioma or metastatic PPGL.\n* Severe cardiac disease (e.g., severe valvular disease, severe heart failure) that could independently cause intraoperative HDI.\n* Pregnancy or breastfeeding.\n* Mental illness, cognitive impairment, or communication barriers that prevent compliance with study procedures.\n* Refusal to undergo CGM monitoring or AI agent assessment.\n* Major illness (e.g., acute myocardial infarction, stroke, severe infection) within 3 months prior to surgery.\n* Severe hepatic or renal insufficiency (Child-Pugh class C, eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²).","99 Years",{"count":54,"type":22},200,"6 Weeks","The study will enroll patients scheduled for PPGL removal surgery at Peking Union Medical College Hospital. Before surgery, researchers will use a 6-variable model to predict the patient's risk of experiencing severe blood pressure swings during the operation. During surgery, a real-time early warning tool will be tested for its ability to accurately predict blood pressure changes 60 seconds in advance. The study will also explore the value of continuous glucose monitoring (CGM) in understanding blood pressure fluctuations and evaluate the performance of an artificial intelligence (AI) agent for preoperative anesthesia assessment, comparing its accuracy, consistency, and efficiency against that of human anesthesiologists.\n\nParticipation involves no changes to the patient's standard surgical or medical care. It includes collecting clinical data, wearing a CGM sensor from the day before to the day after surgery, and having the preoperative assessment performed by both the AI agent and anesthesiologists.",[58,59,60,28],"Pheochromocytoma","Paraganglioma","Hemodynamic Instability",[58,59,60,62,63,64,65],"Predictive Model","Artificial Intelligence","Continuous Glucose Monitoring","Prospective Cohort","NOT_YET_RECRUITING","2026-04-02",{"date":69,"type":36},"2026-04-07",{"date":71,"type":22},"2026-04",{"date":73,"type":22},"2028-02",{"name":75,"class":43},"Peking Union Medical College Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100622998","gls-in-difficult-cpb-weaning-100622998","NCT07390903","GLS in Difficult CPB Weaning","Global Longitudinal Strain as a Predictor of Difficult Separating From Cardiopulmonary Bypass","Inclusion Criteria\n\n* Age \\> 18 years.\n* Scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CPB).\n* Provided written informed consent to participate.\n* Eligible surgical procedures include:\n\n  * Isolated mitral valve replacement or repair.\n  * Isolated aortic valve replacement or repair.\n  * Isolated coronary artery bypass grafting (CABG).\n  * Combined valve and CABG surgery.\n  * Multiple valve replacement or repair.\n  * Surgery involving the ascending aorta or aortic arch.\n\nExclusion Criteria\n\n* Emergency cardiac surgery.\n* Redo cardiac surgery.\n* Contraindications to transesophageal echocardiography (TEE).\n* Critical preoperative conditions, including:\n\n  * Ongoing inotropic drug therapy.\n  * Preoperative mechanical circulatory support (e.g., IABP, ECMO, VAD).\n  * Requirement for mechanical ventilation.\n  * Preoperative atrial fibrillation.",{"count":84,"type":22},213,"The goal of this observational study is to learn whether global longitudinal strain (GLS), measured by echocardiography, can predict difficulty separating from cardiopulmonary bypass (CPB) in adults undergoing elective cardiac surgery.\n\nThe main questions it aims to answer are:\n\n* Can preoperative GLS measurement predict difficult separation from CPB?\n* Are GLS values associated with outcomes such as intensive care unit (ICU) stay, hospital stay, cardiac biomarkers, or 30-day mortality?\n\nParticipants will:\n\n* Undergo standard cardiac surgery requiring CPB\n* Have echocardiographic assessments (TTE before and after surgery)\n* Have their recovery and outcomes monitored, including ICU and hospital stay, postoperative labs, and survival within 30 days",[87,88,89,90,28,91],"Cardiopulmonary Bypass","Coronary Artery Bypass","Heart Valve Diseases","Echocardiography","Postoperative Complications (Cardiopulmonary)","2026-02-01",{"date":94,"type":36},"2026-02-05",{"date":94,"type":22},{"date":97,"type":22},"2026-08-30",{"name":99,"class":100},"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","OTHER_GOV",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100606915","clinical-trial-of-visor-vs-furs-for-upper-urinary-tract-stone-100606915","NCT07181759","Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone","Prospective Randomized Controlled Clinical Trial on the Treatment of Upper Urinary Tract Stones With VISOR and fURS","VISOR","Inclusion Criteria:\n\n* Patients with upper urinary tract stones and a cumulative stone diameter ≤3 cm;\n* Patients scheduled to undergo \"flexible ureteroscopic holmium laser lithotripsy\";\n* Age ≥18 years;\n* Patients without psychiatric disorders or language dysfunction, capable of understanding the study and providing informed consent.\n\nExclusion Criteria:\n\n* Patients requiring bilateral lithotripsy in a single-stage ureteroscopic procedure;\n* Ipsilateral hydronephrosis with \\>4 cm renal pelvic separation;\n* Patients with a history of open or laparoscopic renal and\u002For ureteral surgery;\n* Fever (body temperature ≥38°C) due to urinary tract infection or other causes within one week prior to surgery;\n* Pregnant women;\n* Patients with severe systemic diseases, cardiac diseases, pulmonary insufficiency, or vital organ failure unable to tolerate anesthesia or surgery (ASA score ≥3);\n* Patients with anatomical abnormalities such as polycystic kidney, horseshoe kidney, or ectopic kidney;\n* Patients with coagulation disorders (e.g., INR \\>2.0 or platelet count \\\u003C80×10⁹\u002FL);\n* Patients currently participating in other device or drug clinical trials;\n* Patients deemed ineligible for the trial by the investigator.",{"count":111,"type":22},100,"INTERVENTIONAL",[114],"NA","This prospective randomized controlled clinical study aims to evaluate the safety and efficacy of a novel Vortex Intelligence Stone Optimized Removal (VISOR,The experimental group) system compared to a single-use ureterorenoscope (the control) for treating upper urinary tract stones.\n\nA total of 100 patients with upper urinary tract stones (cumulative stone diameter ≤3 cm) will be enrolled and randomly assigned in a 1:1 ratio to either the experimental group (n=50) or the control group (n=50). The experimental group will undergo surgery using the innovative system, which integrates irrigation-suction, pressure monitoring-regulation, and lithotripsy-evacuation functions. The control group will be treated with a conventional single-use ureterorenoscope.\n\nThe primary outcome measure is the immediate stone-free rate (SFR), defined as the proportion of patients with residual fragments \\\u003C4 mm on renal non-contrast computed tomography (NCCT) performed within 24 hours postoperatively. Key secondary endpoints include the SFR at 3 months, operative and lithotripsy times, total laser energy used, intraoperative ureteral injury (Traxer grading), postoperative pain scores, incidence of fever (\\>38.0°C), and overall complication rates (Clavien-Dindo classification).\n\nPatient follow-up assessments will be conducted at 24 hours, 21±7 days, and 90±14 days post-surgery to monitor stone clearance, complications, and recovery. This study seeks to determine if the novel system offers superior stone clearance while maintaining a safe renal pelvic pressure profile, potentially improving outcomes for patients with larger renal stones treated ureteroscopically.",[117,118,119,28],"Urolithiasis, Calcium Oxalate","Ureteroscopy","Therapeutic Irrigation",[121,122,123,124,125,108,126],"Ureterorenoscopy","Upper urinary tract calculi","Intrarenal pressure","Stone-free rate (SFR)","Lithotripsy","Vortex intelligence Stone Optimized Removal(VISOR）","2025-09-12",{"date":129,"type":36},"2025-09-18",{"date":131,"type":22},"2025-09-20",{"date":133,"type":22},"2026-12-31",{"name":135,"class":43},"Ningbo No. 1 Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":112,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100535860","phase-4-appropriate-dosage-of-vasopressor-in-neonates-and-infants-100535860","NCT06257316","Appropriate Dosage of Vasopressor in Neonates and Infants","A Study on the Appropriate Dosage of Vasopressors to Maintain Adequate Cerebral Blood Flow During Surgery and Anesthesia in Neonates and Infants","Inclusion Criteria:\n\n* Newborns and infants under 2 years of age undergoing surgery under general anesthesia at Seoul National University Hospital\n\nExclusion Criteria:\n\n* Premature infants with a gestational age of less than 37 weeks\n* Children with a history of brain disease (hydrocephalus, brain tumor, etc.)\n* Patients with a history of hypoxic\u002Fischemic brain injury\n* Children with fused fontanels\n* Children with uncorrected congenital cardiac malformations such as patent ductus arteriosus\n* Patients with hypersensitivity to ephedrine and its components\n* Patients with hypertension\n* Patients with thyrotoxicosis\n* Patients with renal impairment and those taking thyroid medication\n* Glaucoma patients\n* Diabetic patients\n* Patients with prostatic hyperplasia\n* Patients with chromophobe cell tumors\n* Patients taking or within 2 weeks of discontinuing monoamine oxidase inhibitors\n* Patients with ischemic heart disease\n* Patients receiving foxglove preparations\n* Patients with cardiac disease\n* Patients receiving inotropic agents and those with abnormal baseline blood pressure\n* Those who are taking or need to take concomitant contraindicated medications\n* Those who require halogenated anesthetics such as chloroform, cyclopropane, and halothane because concomitant administration may cause ventricular arrhythmias.\n* Those who are expected to require these agents because they may cause arrhythmias or cardiac arrest when coadministered with catecholamines such as epinephrine and isoproterenol.","2 Years",{"count":145,"type":22},132,[147],"PHASE4","In this study, the investigators will evaluate cerebral blood flow before and after drug infusion using ultrasound to suggest blood pressure criteria and dosage of ephedrine, a vasopressor, to maintain adequate cerebral blood flow in neonates and infants undergoing surgery and anesthesia.",[150,151,28],"Hypotension","Neonatal Hypotension","2024-02-13",{"date":154,"type":36},"2024-02-15",{"date":154,"type":22},{"date":157,"type":22},"2028-02-28",{"name":159,"class":43},"Seoul National University Hospital"]